However, the widespread success of these agents was not achieved until the early 21st century after FDA approval of gemtuzumab ozogamicin in 2000 for CD33-positive acute myeloid leukemia (later withdrawn in 2010, but reapproved by the FDA in 2017), brentuximab vedotin in 2011 for relapsed/refractory Hodgkin’s lymphoma, and tratuzumab emtansine in 2013 for HER2 positive breast cancer [52,53,54,55]. This evidence concerns the gene ERBB2 and breast carcinoma.